Stock Watch: The Pandemic’s Effects On Big Pharma – A Year In
Negative Effects On Revenue Were Partly Balanced In Other Areas
Executive Summary
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.
You may also be interested in...
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: The Great Post-Pandemic Pharmaceutical Marketing Debate
Virtual marketing was the logical way to interact with healthcare professionals during the pandemic. It may stay after the pandemic but could be an additional expense.
Stock Watch: The Pandemic – Where Generics Failed To Reign
If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.